Decrease in Serum Bicarbonate In a study of concomitant therapy of 10 mg dapagliflozin with exenatide extended-release (on a background of metformin), four patients (1.7%) on concomitant therapy had a serum bicarbonate value of less than or equal to 13 mEq/L compared to one each (0.4%) in the dapagliflozin and exenatide-extended release treatment groups
For instance, key questions that need to be answered include: What are the anti-inflammatory effects of GLP-1s, and how do they impact those with autoimmune disease
10.1016/0026-0495(91)90033-S 99
SURMOUNT (obesity): Multiple trials enrolling over 5,000 patients
Other side effects to monitor Patients switching between formulations should also be aware of potential headaches associated with GLP-1 therapy , tirzepatide body aches , muscle pain , insomnia , and semaglutide-related sleep disruption
Br J Pharmacol 153 (Suppl 1):S298S309